Clinical trials: Influenza Prevention, open to volunteers
- Condition Influenza Prevention
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Respiratory Infection Virus, COVID-19
Noseguard for Prevention of Respiratory Infections in Real-World Use
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and…
- Conditions
- Respiratory Infection Virus, COVID-19, Influenza
- Trial name
- NCT07516977
- Testing
- Noseguard and Noseguard Night
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Participants
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- NCT07300085
- Testing
- Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection
- Where
- 2 sites in United States
- Volunteers
- 710 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza Prevention
Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC).
- Trial name
- NCT07730346
- Testing
- Sebaloxavir marboxil
- Where
- China
- Volunteers
- 858 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT06574503
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- ANCHOR (NCT07159763)
- Testing
- MK-1406
- Where
- 211 sites in United States, Argentina and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prevention of Influenza
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
- Trial name
- NCT07133802
- Testing
- Test Group
- Volunteers
- 6,680 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.